Image

Global Optic Nerve Disorders Treatment Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60
  • Pharmaceutical
  • Upcoming Report
  • Apr 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Optic Nerve Disorders Treatment Market, By Indication (Glaucoma, Optic Neuritis, Optic Nerve Gliomas, Optic Nerve Drusen, Optic Nerve Coloboma, Optic Atrophy, Others), Diagnosis (Imaging Tests, Ophthalmoscopy, Eye exams), Drug Class (Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Antibiotics, Corticosteroids, Others), Route of Administration (Oral, Topical, Others), Dosage Form (Tablets, Injections, Solution, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Optic Nerve Disorders Treatment Market

Market Analysis and Size

In recent years, the optic nerve disorders treatment market is anticipated to grow rapidly during the forecast period. The retina and optic nerve are among the critical elements of the eye. The retina collects the image, and the captured image is transmitted to the brain for analysis. Trauma, multiple sclerosis (M.S.), and glaucoma affect the optic nerve. As per the World Health Organization (WHO), 2.2 billion individuals were affected by vision impairment or blindness in 2019. Cataracts, uncorrected refractive errors, corneal opacification, glaucoma, and other conditions are among the most common causes of vision impairment.

Data Bridge Market Research analyses that the optic nerve disorders treatment market was valued at USD 1.92 billion in 2021 and is expected to reach USD 2.73 billion by 2029, registering a CAGR of 4.50% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Market Definition

The second cranial nerve, the optic nerve of the eye, assists in the transmission of sensory information to the brain for vision. During fetal development, the optic vesicle of the forebrain develops into this nerve. Loss of vision can occur if the optic nerve or its routes to the brain are damaged. Glaucoma, optic nerve atrophy, optic neuritis, and optic nerve head drusen are all common optic nerve illnesses found throughout the world. The majority of these illnesses are treated symptomatically. The treatments may not enhance eyesight, but they can help prevent visual loss as the illness progresses.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2014)

Quantitative Units

Revenue in USD Billion, Volumes in Units, Pricing in USD

Segments Covered

Indication (Glaucoma, Optic Neuritis, Optic Nerve Gliomas, Optic Nerve Drusen, Optic Nerve Coloboma, Optic Atrophy, Others), Diagnosis (Imaging Tests, Ophthalmoscopy, Eye exams), Drug Class (Beta Blockers, Prostaglandins, Alpha Adrenergic Agonist, Carbonic Anhydrase Inhibitors, Antibiotics, Corticosteroids, Others), Route of Administration (Oral, Topical, Others), Dosage Form (Tablets, Injections, Solution, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International GmbH. (Germany), Apotex Inc. (Canada), AstraZeneca (U.K.), Johnson & Johnson (U.S.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), LEO Pharma A/S (Denmark), Bausch Health Companies Inc. (Canada), Allergan (Ireland), Eli Lilly and Company (U.S.), Aurobindo Pharma (India), Lupin (India)

Market Opportunities

 

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches

Optic Nerve Disorders Treatment Market Dynamics

Drivers

  • Increasing prevalence of eye diseases

The rising prevalence of eye diseases is estimated to enhance the growth of the optic nerve disorders treatment market. As per the American Academy of Ophthalmology, approximately 7.32 million people will be diagnosed with primary open-angle glaucoma (POAG) in 2019, with the highest rates among people aged 70 to 79 years old (32%), women (50%), and Hispanics (50 percent ).

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of optic nerve disorders treatment market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

  • Rising number of cases of glaucoma

The surging number of glaucoma and multiple sclerosis (M.S.) cases is anticipated to expand the optic nerve disorders treatment market. Glaucoma is referred to a medical condition which is characterized by a rise in intraocular fluid pressure. The inflammation of the optic nerve causes optic neuritis, while other illnesses are triggered by physical injury to the optic nerve or the development of protein or calcium pockets in the optic nerve.

  • Growing number of geriatric population

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to the optic nerve disorders treatment market, further estimated to enhance its growth rate.

  • High prevalence of multiple sclerosis (M.S.)

The high prevalence of multiple sclerosis (M.S.) is expected to be a major driver for the optic nerve disorders treatment market’s growth. M.S. is an autoimmune disease in which the immune system assaults healthy bodily components, resulting in eyesight loss or decrease in more than half of the cases. As a result, manufacturers are expanding their production capacity in order to develop immunosuppressive medications that improve patients' quality of life. In September 2019, Roche, a Swiss multinational healthcare company, announced the results of clinical studies for Ocrevus, an immunosuppressive medicine, to better understand its impact in relapsing and progressive M.S.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the optic nerve disorders treatment market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate. 

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for the optic nerve disorders treatment market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the optic nerve disorders treatment market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This optic nerve disorders treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the optic nerve disorders treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Optic nerve disorders treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Optic Nerve Disorders Treatment Market

Over the projected period, the optic nerve disorders treatment market was expected to be constrained by the COVID-19 outbreak. Since its emergence in December 2019, the COVID-19  virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. COVID-19, a new coronavirus, was identified as the causal agent in the pneumonia cases. This virus spread quickly over the world, killing a large number of people. COVID-19 was labelled a global pandemic by the World Health Organization (WHO) in March 2020, and rigorous measures to prevent the disease's spread were recommended. Since then, the pandemic has delayed the expansion of the healthcare sector and disrupted the supply chain. Furthermore, governments in many nations had imposed nationwide lockdowns to halt the spread of COVID-19. Similarly, healthcare organizations in numerous nations throughout the world were having difficulty continuing their supply chain activities. The supply chain slowness hampered the optic nerve disorders treatment market.

Recent Development

  • In August 2020, the U.S. Food and Drug Administration (FDA) approved Enspryng (satralizumab-mwge) for treating neuromyelitis optica spectrum disorder (NMOSD) in adults. Enspryng was given fast track designation, which expedites the development and review of drugs that are intended to treat a serious condition and show promise of meeting an unmet medical need. The drug was also designated as an orphan drug, which provides financial incentives to help and stimulate drug development for rare disorders.

Global Optic Nerve Disorders Treatment Market Scope

The optic nerve disorders treatment market is segmented on the basis of indication, drug class, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Indication

  • Glaucoma
  • Optic Neuritis
  • Optic Nerve Gliomas
  • Optic Nerve Drusen
  • Optic Nerve Coloboma
  • Optic Atrophy
  • Others

Drug Class

  • Beta Blockers
  • Prostaglandins
  • Alpha Adrenergic Agonist
  • Carbonic Anhydrase Inhibitors
  • Antibiotics
  • Corticosteroids
  • Others

Diagnosis

Dosage form

  • Tablets
  • Injections
  • Solution
  • Others

Route of Administration

  • Oral
  • Topical
  • Others

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Optic Nerve Disorders Treatment Market Regional Analysis/Insights

The optic nerve disorders treatment market is analysed and market size insights and trends are provided by country, indication, drug class, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the optic nerve disorders treatment market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the optic nerve disorders treatment market because of the presence of major key players and increasing patient population in this region. Additionally, rising healthcare expenditure will further propel the market’s growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022 to 2029 due to the increasing number of government initiatives in this region. Also, development of healthcare infrastructure and rising population will further propel the market’s growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Optic Nerve Disorders Treatment Market Share Analysis

The Optic nerve disorders treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to optic nerve disorders treatment market.

Some of the major players operating in the optic nerve disorders treatment market are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Sanofi (France)
  • Pfizer Inc. (U.S.)
  • GlaxoSmithKline plc (UK)
  • Novartis AG (Switzerland)
  • Zydus Cadila (India)
  • Boehringer Ingelheim International GmbH. (Germany)
  • Apotex Inc. (Canada)
  • AstraZeneca (U.K.)
  • Johnson & Johnson (U.S.)
  • Bayer AG (Germany)
  • Sun Pharmaceutical Industries Ltd. (India)
  • LEO Pharma A/S (Denmark)
  • Bausch Health Companies Inc. (Canada)
  • Allergan (Ireland)
  • Eli Lilly and Company (U.S.)
  • Aurobindo Pharma (India)
  • Lupin (India)


SKU-

Why Choose Us


Frequently Asked Questions

The market value for Optic Nerve Disorders Treatment Market is expected USD 2.73 billion by 2029.
The Optic Nerve Disorders Treatment Market is to grow at a CAGR of 4.50% during the forecast by 2029.
The major players operating in the Optic Nerve Disorders Treatment Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International GmbH. (Germany), Apotex Inc. (Canada), AstraZeneca (U.K.), Johnson & Johnson (U.S.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), LEO Pharma A/S (Denmark), Bausch Health Companies Inc. (Canada), Allergan (Ireland), Eli Lilly and Company (U.S.), Aurobindo Pharma (India), Lupin (India).
The major countries covered in the Optic Nerve Disorders Treatment Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.